Doximity price target raised to $67 from $59 at Canaccord

Canaccord analyst Richard Close raised the firm’s price target on Doximity (DOCS) to $67 from $59 and keeps a Hold rating on the shares. The firm met with managment and discussed Doximity’s AI clinical reference acquisition of Pathway and its longer-term AI opportunity. The company’s growing technology tool set should continue to drive increasing clinician engagement. As a result, demand for the company’s marketing and brand awareness solutions should grow as Pharma marketing increasingly shifts to digital formats.